top of page
Button
Button

Smith (Sm) Antibody

Test Includes:

Viruses Included in Panel

Organisms Included in Panel

Test Utility

SmDp-S antibodies offer a highly specific, but comparatively insensitive, clinical marker for SLE.  Indeed, their presence constitutes one of the revised American College of Rheumatology (ACR) criteria, even though their overall presence ranges from 20% to 30% in SLE. Anti-Sm antibodies react with proteins SmBB’ and SmD. However, tests which include the antigens SmBB’ fail to differentiate patients with SLE from those with other autoimmune diseases. Only SmD is considered the most SLE-specific antigen. The ability of SmD-based antibody tests to differentiate between SLE and other autoimmune diseases can be improved by using a SmD3 peptide as antigen.  This is a semi-quantitative test.

Urine Drug Screen Profile Includes:

Methodology

Immunoassay, Fluorescent; EliA method

Methodology

Screen Test Name
Assay Type
ETG
DRI
Amphetamine
DRI
Barbiturates
DRI
Benzodiazepine
DRI
Cotinine
DRI
Cocaine
DRI
Methadone
DRI
Opiate
DRI
Oxycodone
DRI
THC
DRI
Fentanyl
DRI
Buprenorphine
CEDIA
PCP
DRI

Individual Test Information Including Methodology & Reference Ranges

Reflex to UTI Criteria

Specimen Collection and Preparation

  • Venipuncture, Gel barrier tube preferred. 

  • Plain red top also acceptable. 

  • 5.0mL blood minimum. 

  • Pour serum into plastic pour off tube, label with source of serum (gold top or red top).

Specimen Storage and Stability

  • Centrifuge and transport to laboratory at room temperature. 

  • Samples are stable for 1 week when stored at 2-8C. 


Note: samples are stored at 2-8C for 7 days before disposal

Specimen Rejection

  • Improper/incomplete labeling; 

  • improper sample type; 

  • Quantity insufficient (QNS); 

  • lipemic or hemolyzed samples cannot be used.

Reference Range (Cutoff)

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
Cocaine
300

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
Benzodiazepine
200

​

Screen Test Name
Cutoff (ng/mL)
Buprenorphine
5

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
Amphetamine
500

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
Barbiturates
200

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
ETG
500

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
ETG
500

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
EDDP
100

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
Fentanyl
1

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
Methadone
300

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
PCP
25

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
Opiate
300

​

Screen Test Name
Screen Test Name Cutoff (ng/mL)
Oxycodone
300

​

Screen Test Name
Cutoff (ng/mL)
Methamphetamine
500

​

Screen Test Name
Cutoff (ng/mL)
THC
50

​

Screen Test Name
Cutoff (ng/mL)
ETG
500
Amphetamine
500
Barbiturates
200
Benzodiazepine
200
Cotinine
500
Cocaine
300
Methadone
300
Opiate
300
Oxycodone
300
THC
50
Fentanyl
1
Buprenorphine
5
PCP
25

Reference Range

The assay provides a numerical result in U/mL and interpretative comments based on the numerical result: 


 <7.0 U/mL= Negative; 7.0-10.0 U/mL = Equivocal; >10.0 U/mL = Positive


A definitive clinical diagnosis should not be based on the results of a single diagnostic method but should only be made by the physician after all clinical and laboratory findings have been evaluated.


It is recommended to repeat equivocal results, after 8-12 weeks.

Parameter 
Reference Range 
Glucose 
Negative 
Bilirubin 
Negative 
Ketones 
Negative 
Specific Gravity 
1.005 - 1.030 
Blood 
Negative 
pH 
5.0 - 8.0 
Protein 
Negative 
Urobilinogen 
0.0 - 1.0 mg/dL 
Nitrate 
Negative 
Leukocyte Esterase 
Negative 
Microscopic Evaluation 
WBC 
Negative 
RBC 
Negative 
Hylaine Casts 
Negative 
All other Parameters 
Negative 

​

Parameter
Reference Range
Microscopic Evaluation
WBC
Negative
RBC
Negative
Hylaine Casts
Negative
All other Parameters
Negative

​

Parameter
Reference Range
Glucose
Negative
Bilirubin
Negative
Ketones
Negative
Specific Gravity
1.005 - 1.030
Blood
Negative
pH
5.0 - 8.0
Protein
Negative
Urobilinogen
0.0 - 1.0 mg/dL
Nitrate
Negative
Leukocyte Esterase
Negative

​

CBC
Adult Male
Adult Female
Adult Female 10^3/uL
Adult Female %
WBC
3.5-10.5 10³/uL
3.5-10.5 10³/uL
RBC
4.32-5.72 10⁶/uL
3.9-5.03 10⁶/uL
HGB
13.5-17.5 g/dL
12.0-15.5 g/dL
HCT
38.8-50.0%
34.9-44.5%
MCV
81.2-95.1 fL
81.6-98.3fL
MCH
27-35 pg
27-35 pg
MCHC
31-36 g/dL
31-36 g/dL
RDW
11.8-15.6%
11.9-15.5%
PLT
150-450 10³/uL
150-450 10³/uL
Differential
Adult Male 10³/uL
Adult Male %
Neutrophils
1.7-7.0
55-70
1.7-7.0
55-70
Lymphocytes
0.9-2.9
20-40
0.9-2.9
20-40
Monocytes
0.3-0.9
2-8
0.3-0.9
2-8
Eosinophils
0.0-0.5
1-4
0.0-0.5
1-4
Basophils
0.0-0.3
0.5-1
0-0.3
0.5-1
Immature Granulocytes
0-0.5
<1.0
0-0.5
<1.0

​

CBC
Adult Male
Adult Female
WBC
3.5-10.5 10³/uL
3.5-10.5 10³/uL
RBC
4.32-5.72 10⁶/uL
3.9-5.03 10⁶/uL
HGB
13.5-17.5 g/dL
12.0-15.5 g/dL
HCT
38.8-50.0 %
34.9-44.5%
MCV
81.2-95.1 fL
81.6-98.3 fL
MCH
27-35 pg
27-35 pg
MCHC
31-36 g/dL
31-36 g/dL
RDW
11.8-15.6 %
11.9-15.5%
PLT
150-450 10³/uL
150-450 10³/uL

​

Test
Adult Male
Adult Female
ESR
0-10 mm/hr
0-20 mm/hr

​

CBC
Adult Male
Adult Female
HGB
13.5-17.5 g/dL
12.0-15.5 g/dL
HCT
38.8-50.0%
34.9-44.5%

​

Test
Adult Male
Adult Female
Reticulocyte Count
0.0216 – 0.0858 10^6/uL
0.0195 – 0.0755 10^6/uL

Testing Description

State Reportable Infection

Pediatric Range

Test Code

P-VHL-9011

Performed

Monday-Friday

Contacts

Vibra Health Laboratory

1307- A, Allen Dr

Troy, MI 48083

(248) 846-0663

Last Updated

3/31/26 v.1

bottom of page